公开(公告)号：US20200079848A1

公开(公告)日：2020-03-12

申请号：US16506754

申请日：2019-07-09

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC: C07K16/28 ,  A61K47/68 ,  A61K39/395 ,  A61K45/06 ,  G01N33/577 ,  G01N33/563 ,  A61P35/00

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

公开(公告)号：US20230119066A1

公开(公告)日：2023-04-20

申请号：US17914257

申请日：2021-03-22

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Ruth Yin-Zong Lan ,  Olufemi A. Adelakun ,  Ishita Barman ,  Joseph Campbell ,  SJ Jian Zhe Diong ,  Felix Findeisen ,  Danielle M. Greenawalt ,  Renu Jain ,  Amy D. Jhatakia ,  John K. Lee ,  Peter S.K. Lee ,  Linda Liang ,  Kai Lu ,  Bryan McDonald ,  Paul Mesko ,  Arvind Rajpal ,  Sharmila Sambanthamoorthy ,  Mark J. Selby ,  Nathan O. Siemers ,  Pavel Strop ,  Gaby A. Terracina ,  Xi-Tao Wang

IPC: C07K16/28 ,  A61P35/00

Abstract: This disclosure provides isolated antibodies, for example, monoclonal antibodies, that specifically bind to the C-C Motif Chemokine Receptor 8 (CCR8) expressed on the surface of a cell and mediate depletion of the CCR8-expressing cell by anti-body-dependent cellular cytotoxicity (ADCC). The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CCR8 antibody as monotherapy or in combination with an anti-cancer agent such as an immune checkpoint inhibitor, for example, an anti-PD-1 or anti-PD-L1 antibody.

公开(公告)号：US20230174647A1

公开(公告)日：2023-06-08

申请号：US17845742

申请日：2022-06-21

Applicant: Five Prime Therapeutics, Inc. ,  Bristol-Myers Squibb Company

Inventor： Xiao Min Schebye ,  Diana Yuhui Chen ,  Andrew Rankin ,  Xiaodi Deng ,  Joseph Toth ,  Linda Liang ,  Michelle Minhua Han ,  Christine Bee ,  Hong-An Truong ,  Mark J. Selby ,  Nils Lonberg ,  Guodong Chen ,  Richard Y. Huang ,  Ekaterina G. Deyanova ,  Alan J. Korman

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  G01N33/563 ,  G01N33/577

CPC classification number: C07K16/2803 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/6803 ,  A61P35/00 ,  C07K16/2827 ,  G01N33/563 ,  G01N33/577 ,  A61K2039/505

Abstract: The present application relates to antibodies specifically binding to immunoglobulin-like transcript 4 (ILT4), which is also known as LILRB2, LIR2, MIR10, and CD85d, and corresponding nucleic acids, host cells, compositions, and uses. In some embodiments, the antibodies bind specifically to human ILT4, but do not significantly bind to ILT2, ILT3, or ILT5, or to other members of the LILRA or LILRB families.

公开(公告)号：US20210395392A1

公开(公告)日：2021-12-23

申请号：US17284119

申请日：2019-10-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Thomas E. Spires, Jr. ,  Michael Quigley ,  Virginie Lafont ,  Ginger C. Rakestraw ,  Linda Liang ,  Karen A. Augustine-Rauch

IPC: C07K16/40 ,  A61K47/68 ,  A61P35/00 ,  C07K16/28

Abstract: This disclosure provides isolated antibodies that bind specifically to MerTK expressed on the surface of a cell and inhibit efferocytosis by the MerTK-expressing cell. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-MerTK antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1 or anti-PD-L1 antibody.